Finance

Lists
MCK:NYSE
McKesson Corp
1 004,84 USD
+0,62%
(+6,20) 1D
1 004,84 USD
0,00% (0,00)
After hours
Closed: 16-окт., 16:00:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCK...
Open
1 012,20 USD
High
1 014,99 USD
Low
999,27 USD
Mkt. cap
117,15 млд
Avg. vol.
822,68 миң
Volume
621,36 миң
Dividend
0,37%
Quarterly dividend
0,94 USD
Ex-dividend date
2026-ж., 1-сен.
P/E ratio
26,91
52-wk high
1 014,99 USD
52-wk low
723,68 USD
EPS
37,35 USD
Beta
0,30
Shares outstanding
116,59 млн
No. of employees
42 миң
Open
1 012,20 USD
High
1 014,99 USD
Low
999,27 USD
Mkt. cap
117,15 млд
Avg. vol.
822,68 миң
Volume
621,36 миң
Dividend
0,37%
Quarterly dividend
0,94 USD
Ex-dividend date
2026-ж., 1-сен.
P/E ratio
26,91
52-wk high
1 014,99 USD
52-wk low
723,68 USD
EPS
37,35 USD
Beta
0,30
Shares outstanding
116,59 млн
No. of employees
42 миң
News stories
From web sources and news partners
Profile
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK". McKesson provides extensive network of infrastructure for the healthcare industry and was an early adopter of technologies, including barcode scanning for distribution, pharmacy robotics, and RFID tags. The company has been named in a federal lawsuit for profiting from the opioid epidemic in the United States. Throughout the COVID-19 pandemic, McKesson was a key vaccine distributor, serving as the US government's centralized distributor for hundreds of millions of COVID-19 vaccine doses and ancillary supply kits for over a billion doses. Wikipedia
About McKesson Corp
CEOBrian S. Tyler
Employees42,3 миң
Founded1835
Headquarters-
SectorHealth care provider
Analyst ratings
Based on 15 analysts giving stock ratings to MCK in the past 3 months
Strong buy
Buy
12
Hold
3
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for MCK in the last 3 months.
Highest
Current 1 004,84 USD
1 200,00 USD (+19,42%)
Average
996,86 USD (-0,79%)
Lowest
845,00 USD (-15,91%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kevin Caliendo
UBS
Buy
Maintained
1 200,00 USD
+19,4%
10/16/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
1 070,00 USD
+6,5%
10/07/2026
Ryan Halsted
RBC Capital
Hold
Maintained
845,00 USD
-15,9%
10/06/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
1 000,00 USD
-0,5%
10/06/2026
George Hill
Deutsche Bank
Buy
Maintained
913,00 USD
-9,1%
10/06/2026
Erin Wright
Morgan Stanley
Buy
Maintained
977,00 USD
-2,8%
10/06/2026
Allen Lutz
Bank of America Securities
Buy
Maintained
1 050,00 USD
+4,5%
10/05/2026
Ryan Daniels
William Blair
Buy
Maintained
-
-
10/05/2026
Glen Santangelo
Barclays
Buy
Maintained
1 000,00 USD
-0,5%
08/18/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
1 042,00 USD
+3,7%
08/10/2026
Stephen Baxter
Wells Fargo
Hold
Reiterated
933,00 USD
-7,1%
08/11/2026
Daniel Grosslight
Citi
Buy
Reiterated
1 000,00 USD
-0,5%
08/10/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
1 015,00 USD
+1%
08/06/2026
Steven Valiquette
Mizuho Securities
Hold
Maintained
905,00 USD
-9,9%
08/05/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
1 006,00 USD
+0,1%
08/06/2026
Max Smock
William Blair
Buy
Reiterated
-
-
05/08/2026
Last report
2026-ж., 5-авг.
Fiscal period
Q1 2027
9,93 USD / 9,54 USD
+4,14%beat
Revenue / Est. (USD)
105,38 млд / 103,74 млд
+1,58%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
103,15 млд
106,16 млд
96,30 млд
105,38 млд
Cost of goods sold
99,61 млд
102,49 млд
92,25 млд
101,70 млд
Cost of revenue
99,61 млд
102,49 млд
92,25 млд
101,70 млд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,12 млд
2,03 млд
1,92 млд
2,26 млд
Operating expense
2,12 млд
2,03 млд
1,92 млд
2,26 млд
Total operating expenses
101,73 млд
104,52 млд
94,17 млд
103,96 млд
Operating income
1,42 млд
1,64 млд
2,13 млд
1,42 млд
Other non operating income
62,00 млн
74,00 млн
-156,00 млн
66,00 млн
EBT including unusual items
1,40 млд
1,63 млд
2,12 млд
1,31 млд
EBT excluding unusual items
1,40 млд
1,65 млд
2,10 млд
1,41 млд
Income tax expense
232,00 млн
380,00 млн
270,00 млн
276,00 млн
Effective tax rate
16,63%
23,31%
12,71%
21,10%
Other operating expenses
-
-
-
-
Net income
1,11 млд
1,19 млд
1,68 млд
614,00 млн
Net profit margin
1,08%
1,12%
1,75%
0,58%
Earnings per share
9,86
9,34
11,69
9,93
Interest and investment income
-
-
179,00 млн
-
Interest expense
-74,00 млн
-63,00 млн
-61,00 млн
-77,00 млн
Net interest expenses
-74,00 млн
-63,00 млн
118,00 млн
-77,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,60 млд
1,83 млд
2,19 млд
1,62 млд
Gain or loss from assets sale
-102,00 млн
-
-488,00 млн
-6,00 млн
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору